Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial
<p><strong>OBJECTIVES:</strong> To evaluate the persistence of immunogenicity three months after third dose boosters.</p> <p><strong>METHODS:</strong> COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a thi...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Other Authors: | |
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2022
|